All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

US CLOs risk catching cold from Valeant woes


Concerns are growing in the US CLO market about the state of pharmaceutical giant Valeant Pharmaceuticals, as the Canadian company's stock price continues to fall, touching the lowest levels in five years in March.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree